Renal Denervation Therapy for the Treatment of Resistant Hypertension: A Position Statement by the Canadian Hypertension Education Program

Canadian Journal of Cardiology

Volumn 30, Issue 1, 2014, Pages 16-21

  Khan, Nadia A ^a   Herman, Robert J ^b   Quinn, Robert R ^b   Rabkin, Simon W ^a   Ravani, Pietro ^b   Tobe, Sheldon W ^c   Feldman, Ross D ^d   Wijeysundera, Harindra C ^e   Padwal, Raj S ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; CANADA; CLINICAL EFFECTIVENESS; EVIDENCE BASED MEDICINE; HUMAN; KIDNEY DENERVATION; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 84890856495     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.07.008     Document Type: Article

References (30)

1. Pimenta E., Calhoun D.A. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012, 125:1594-1596.
2. Daugherty S.L., Powers J.D., Magid D.J., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
3. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
4. Brown M.A., Buddle M.L., Martin A. Is resistant hypertension really resistant?. Am J Hypertens 2001, 14:1263-1269.
5. de la Sierra A., Segura J., Banegas J.R., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
6. Cuspidi C., Macca G., Sampieri L., et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. JHypertens 2001, 19:2063-2070.
7. Pedrosa R.P., Drager L.F., Gonzaga C.C., et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011, 58:811-817.
8. Somers V.K., Dyken M.E., Clary M.P., Abboud F.M. Sympathetic neural mechanisms in obstructive sleep apnea. JClin Invest 1995, 96:1897-1904.
9. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009, 54:690-697.
10. Daskalopoulou S.S., Khan N.A., Quinn R.R., et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012, 28:270-287.
11. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
12. Symplicity HTN-1 Investigators Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension 2011, 57:911-917.
13. Symplicity HTN-2 Investigators, Esler M.D., Krum H., et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
14. Esler M.D., Krum H., Schlaich M., et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012, 126:2976-2982.
15. Kaltenbach B., Franke J., Bertog S.C., Steinberg D.H., Hofmann I., Sievert H. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter Cardiovasc Interv 2013, 81:335-339.
16. Brandt M.C., Mahfoud F., Reda S., et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. JAm Coll Cardiol 2012, 59:901-909.
17. Mahfoud F., Cremers B., Janker J., et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012, 60:419-424.
18. Mahfoud F., Schlaich M., Kindermann I., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
19. Witkowski A., Prejbisz A., Florczak E., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
20. Hering D., Mahfoud F., Walton A.S., et al. Renal denervation in moderate to severe CKD. JAm Soc Nephrol 2012, 23:1250-1257.
21. Mabin T., Sapoval M., Cabane V., Stemmett J., Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention 2012, 8:57-61.
22. Simonetti G., Spinelli A., Gandini R., et al. Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience. Radiol Med 2012, 117:426-444.
23. Thomas G., Shishehbor M.H., Bravo E.L., Nally J.V. Renal denervation to treat resistant hypertension: guarded optimism. Cleve Clin J Med 2012, 79:501-510.
24. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
25. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
26. Mancia G., Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. JHypertens 2004, 22:435-445.
27. Ishikawa J., Carroll D.J., Kuruvilla S., Schwartz J.E., Pickering T.G. Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis. Hypertension 2008, 52:856-864.
28. Ukena C., Mahfoud F., Kindermann I., et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. JAm Coll Cardiol 2011, 58:1176-1182.
29. Persu A., Renkin J., Thijs L., Staessen J.A. Renal denervation ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012, 60:596-606.
30. Kandzari D.E., Bhatt D.L., Sobotka P.A., et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012, 35:528-535.